Earnings Call: Q3 2020

Oct 19, 2020

Welcome to the Royal Philips Third Quarter 2020 Results Conference Call on Monday, 19th October, 2020. During the call hosted by Mr. Franz Van Houten, CEO and Mr. Abhijit Bhattacharya, CFO. Please note, this call will be recorded and a replay will be available on the Investor Relations website of Royal Philips. I will now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir. Good morning, ladies and gentlemen. Welcome to Philips' 3rd quarter results conference call. I'm here with our CEO, Frans van Houten and our CFO, Abhijit Bhattacharya. On today's call, Frans will take you through our strategic and financial highlights for the quarter as well as the targets for accelerated growth, higher profitability and improved cash flow for the 2021 2025 period. Abhijit will then provide more detail on the Q3 financials. After that, we will take your questions. Our press release and the related information and slide deck were published at 7 am CET this morning. Both documents are available on our Investor Relations website. A full transcript of this conference call will be made available by the end of the day on our website. As mentioned in the press release, adjusted EBITDA is defined as income from operations, excluding amortization of acquired intangible assets, impairment of goodwill and other intangible assets, restructuring charges, acquisition related costs and other significant items. The impact of COVID-nineteen on our results is not treated as an adjusting item. Comparable growth for sales and orders are adjusted for currency and portfolio changes. Finally, also as mentioned in the press release, the new targets exclude the Domestic Appliances business. With that, I would like to hand over to Frans. Thanks, Leandro, and good morning to all of you on the call and webcast. I hope that you and your families are keeping safe and well. It's clear that the COVID-nineteen pandemic is far from over, and I'm pleased with how we are performing under challenging circumstances as our teams are focused on delivering what we call our triple duty of care, meeting critical customer needs, safeguarding the health and safety of our employees and ensuring business continuity. The work that we are doing to support health care providers, medical staff, patients and consumers alike remains a top priority for all of us at Philips. In close collaboration with our suppliers and partners, we have ramped up the production volumes of products and solutions to help diagnose, treat, monitor and manage COVID-nineteen patients. We have also continued to create important COVID-nineteen oriented propositions to rapidly respond to customer needs. Moving on to the Q3 financial highlights. We delivered strong growth and improved profitability in the quarter. Overall, comparable sales growth was 10% as we successfully converted our Connected Care order book, saw consumer demand rebounding and elective procedures gradually normalizing. Connected Care grew a very strong 42% in the quarter, driven by the high volume of shipments to fulfill the orders for patient monitors and respiratory care. Sales for Personal Health grew 6%. Our Diagnosis and Treatment businesses delivered encouraging sequential improvement, but still declined 3% in the quarter versus 2019. Comparable equipment order intake grew 3% in the quarter, excluding the impact from the unexpected partial termination of the April 2020 contract with HHS, which was communicated in August. Order intake growth was driven by the demand for patient monitors, hospital ventilators, computed tomography and portable ultrasound systems. Customer response to our innovative products and solutions remains very positive, and we have and we expect to have continued increasing market share in the Professional Healthcare market. Adjusted EBITDA margin was 15.4% in the 3rd quarter, 300 basis points higher than in Q3 2019. Free cash flow increased strongly to €543,000,000 Looking ahead, we continue to see uncertainty and volatility related to the impact of COVID-nineteen across the world. But our order book is solid, and we continue to expect to deliver modest comparable sales growth with an adjusted EBITDA margin of around the level of last year for the full year 2020. Now I would like to provide some color on initiatives to respond to customer needs and support health care professionals. In the quarter, we introduced several new solutions for the intensive care unit, the general ward and the home that feature virtual monitoring capabilities. These include our new rapid equipment deployment kit for ICU ramp ups, allowing hospital staff to quickly deploy critical care patient monitoring capabilities where and when additional care capacity is needed. The kit is a fully configured and ready to deploy ICU patient monitoring servers and a central management monitoring station. Building on our leadership in defibrillators, we launched a new solution for emergency care in the United States consisting of a remote portable vital signs patient monitor and professional defibrillator. This is called the Tempus ALS. It's a complete end to end system that combines innovative hardware and advanced software for emergency responders. Also exciting, we launched major extensions to our industry leading Azurion platform comprising a new range of configurations, addressing more therapeutic areas and more price points and further integrating therapeutic devices and imaging. With the new Azurion, clinicians can easily and seamlessly switch between imaging, physiology, hemodynamics and informatics applications, including state of the art SmartCT 3 d imaging and IntraCyte, a comprehensive suite of clinically proven IFR, FFR, IVAS and co registration modalities. We also expanded our image guided therapy devices portfolio through the acquisition of Intact Vascular, adding an industry first implantable device to treat peripheral artery disease. Moreover, we launched Quickclear, an all in one thrombectomy system for the removal of blood clots from the vessels of the peripheral arterial and venous systems and OmniWire, a solid core pressure wire, another industry first to guide coronary artery procedures. We continue to drive market share in our core businesses through deeper and more comprehensive customer partnerships to enhance patient care and improve care provider productivity. During the Q3, we signed 11 new long term strategic partnerships with hospitals in the United States, Europe and Asia. We announced a multiyear partnership with Tampa General Hospital, cath labs and interventional radiology rooms. We also provide unique workflow solutions and operational performance management services. In Personal Health, we continue to invest in innovation and new product introductions to capitalize on recovery opportunities. In the Q3, we broadened our leading portfolio of power toothbrushes with the exciting launch of the Philips 1 by Sonicare in the United States. This is a battery operated power toothbrush, which is a step up for consumers for that switch from manual brushing and an entry level proposition, thereby allowing us to expand in new consumer segments. The Philips 1 starts at $24.99 and also offers users a subscription service that seamlessly delivers a new brush head and replacement battery right to their door every 3 months. The automatic refill helps keep oral health routines on track and ensures optimal efficacy of brush hands. While we have been working hard on managing our business during these uncertain times, we continue to progress on our strategic and performance road map for the coming years. Our journey to HealthTech Leadership continues as we innovate to drive growth, improve operational excellence and deliver on our transformation. Our strategy to transform Care along the health continuum strongly resonates with customers and has been further validated during the COVID-nineteen crisis. Moreover, we see increased interest in telehealth solutions like tele ICU, teleradiology, telepathology, which can help virtual working of care professionals as well as move care into the community. We are glad to announce our targets for accelerated growth, higher profitability and improved cash flow for the 2021 2025 period ahead of our upcoming Capital Markets Day that will be held virtually in November. We play in attractive market segments with solid growth fundamentals and with long term trends that align with our strategy. We expect these markets to grow around 4% per year, assuming that the world economy returns to growth next year. Building on our transformation and investments over the last few years, we anticipate an acceleration of our average annual comparable sales growth to 5% to 6% with all business segments in that range. This is underpinned by our strategic imperatives to further improve customer and operational excellence, boost growth in our core businesses through innovation, geographical expansion and more customer partnerships and of course, winning with innovative solutions along the health continuum. For 2021, our current view is that group comparable sales will deliver low single digit growth, driven by solid growth in Diagnosis and Treatment and Personal Health, but partly offset by lower Connected Care sales as demand in these businesses normalize from the spike in COVID-nineteen generated demand in 2020. We aim for an average adjusted EBITA margin improvement of 60 to 80 basis points annually, starting in 2021 and reaching high teens by 2025. Looking at the business segments, we expect Diagnosis and Treatment to reach 15% to 17% adjusted EBITA margin, Connected Care to reach 17% to 19% and Personal Health to reach 19% to 20%. This profitability step up is driven by above mentioned growth, delivering operating leverage, increasing return of investments in growth businesses like telehealth and informatics and a further step up in the profitability of Diagnostic Imaging as well as operational excellence resulting in further sizable productivity savings over the next years. Next to this, cash generation will step up to above €2,000,000,000 of free cash flow and organic ROIC will improve to mid to high teens by 2025. We will discuss the strategic and overall performance roadmap in more detail during our Capital Markets Day on November 6, but we did not want to keep the suspense until then so that investors can reflect on it in the meantime. We look forward to a very engaging dialogue during the Capital Markets Day. I'm also very proud to share with you that we are reinforcing our commitments as a purpose driven company with a fully integrated approach to doing business responsibly and sustainably. Our leadership in environmental responsibility is recognized by our stakeholders, and we have been consistently raising the bar. For example, earlier this month, Philips ranked 2 over 5,500 publicly traded companies on the wall on the Wall Street Journal list of the 100 most sustainably managed companies in the world. We expect to deliver on all targets set out in our 20 sixteen-twenty 20 Healthy People Sustainable Planets program by the end of this year. And in September, we announced a comprehensive new set of commitments and targets across the entire spectrum of our environmental, social and corporate governance activities that will guide the execution of our company's strategy. We are enhancing our ambitions to reduce CO2 emissions in line with a 1.5 degree Celsius global warming scenario set out by the Paris Agreement. By 2025, Philips will be 75% powered by renewable energy. All our products and services will be designed in line with eco design requirements. And where we cannot completely eliminate our CO2 emissions, we will offset them by investments in health benefiting environmental projects. When it comes to social responsibility, we commit to improving the lives of 2,000,000,000 people a year by 20 25, including 300,000,000 in underserved communities. We have also set a new goal of 30% gender diversity in senior leadership positions by the end of 2025, up from 25% in 2020. And when it comes to good governance, we commit to being transparent in the tax contributions we make in all countries we operate in. Bringing together all these aspects of responsible and sustainable business into a single framework will not only help us improve lives throughout the world, but it will also reinforce our purpose and strengthen our power of innovation. Ladies and gentlemen, let me also give you an update on the current status of the divestment of the Domestic Appliances businesses. Separation process is on track and expected to be completed in the Q3 of 2021. As planned, we started to engage with interested parties and continue to see good interest for the asset. Domestic Appliances is a solid business and has returned to robust growth with increasing margins in the Q3 based on a strong portfolio of innovations with market leading positions. To round off, I'm pleased that we are delivering to plan and very thankful to our employees. I'm also convinced that Philips is well positioned to serve the current and future needs of hospitals and health systems, next to supporting consumer health and that the growth and margin profile of our company is well underpaid. And with that, I'd like to turn the call to Abhijit. Thank you, Frans, and thank you all for joining us today. Let me start with providing some color on the Q3 comparable sales for the group. Our Diagnosis and Treatment businesses comparable sales declined 3% in the quarter on the back of strong 9% growth in Q3 2019. Diagnostic Imaging sales declined low single digit as growth in computed tomography and diagnostic X-ray was offset by lower volume of installations in MR. Ultrasound sales declined double digit with strong demand for point of care devices more than offset by lower installations of cardiac systems in the quarter. Image guided therapy sales declined low single digit in Q3. The volume of elective procedures continued to recover, being very close to pre COVID-nineteen levels by the end of the quarter. As a result, our Image Guided Therapy Devices business delivered low single digit comparable sales growth in Q3. Sales for Image Guided Therapy Systems improved to a low single digit decline compared to a high teens decline in Q2 as hospitals are gradually resuming installations. Services sales for our Diagnosis and Treatment businesses grew low single digit compared to the same period of 2019. Let me remind you that recurring revenue streams from services represent more than 35% of the total sales of our Diagnosis and Treatment businesses. The sales for Connected Care businesses grew a very strong 42% in Q3 driven by shipments of patient monitors and respiratory care solutions. As mentioned by Frans, we have ramped up the production of these devices to meet urgent demand and fulfill the orders we have on hand for these products. For Personal Health, we saw a steady recovery in demand in the Q3 and helped by the normal pattern of selling ahead of the high season in Q4. Comparable sales increased by 6% with high single digit growth in personal care and domestic appliances and low single digit growth in Oral Healthcare. North America and Western Europe delivered double digit growth. This was partly offset by a decline in growth geographies driven by China. Consumer sales through digital channels grew double digit the quarter and represented 37% of total sales for the Personal Health businesses. This compares to around 30 3% of total sales before the COVID-nineteen pandemic. In store sales grew low single digit in Q3. Given the uncertainty around consumer demand and the slower pace of recovery in China, we continue to expect our Personal Health Business to deliver low single digit comparable sales growth in the Q4 of this year. Moving to orders. As mentioned by France, order intake grew 3% in Q3, excluding the impact from the partial cancellation of the HSS contract. This builds on double digit growth seen in the first half of the year, resulting in double digit growth year to date and a strong order book for the group as depicted on Page 29 of our IR booklet. For reference, if the booking and cancellations of the HHS deal had taken place in the same quarter, so assuming that the booking and cancellation had happened in Q4, The order intake growth for Q2 would have been high single digit compared to the 27% reported previously. Comparable order intake in Connected Care grew by 26% in the quarter. Excluding the impact from the HHS contract, with double digit growth across all businesses, including the impact of the cancellation, order intake for Connected Care declined by 56%. I'm particularly encouraged by another strong quarter in Monitoring and Analytics with more than 20% order growth compared to last year. We also witnessed strong traction in our Connected Care Informatics and Therapeutic Care businesses. Based on this order intake performance, we expect to continue to see solid growth in Connected Care sales in the Q4, although not comparable to the magnitude seen in Q3. Diagnosis and treatment comparable order intake improved to a decline of 5% in Q3 compared to a 20% decline in Q2. Growth in computed tomography, x-ray and portable ultrasound was more than offset by a decline in other parts of the portfolio. High single digit growth in Western Europe was more than offset by a decline in North America and growth geographies. We expect that some areas of the Diagnosis and Treatment businesses will continue to experience a gradual recovery in demand through the Q4, but it's important to note that we have not seen cancellations of orders due to the COVID-nineteen outbreak and continue to experience positive competitive momentum for our portfolio. Let me now turn to the profitability development for the quarter. Adjusted EBITDA for the group was €769,000,000 or 15.4 percent of sales compared to 12.4% in the Q3 of 2019. Looking at the business segments. Connected Care delivered adjusted EBITDA margin of 27.1% of sales compared to 11.3% in the Q3 of 2019 as strong operating leverage and productivity measures initiated from last year more than offset the investments to ramp up production. In Diagnosis and Treatment, the adjusted EBITDA decreased to 9.7% of sales. This was a result of lower sales and lower factory coverage and an unfavorable product mix driven by lower growth of the cardiac ultrasound and image guided therapy portfolios. In Personal Health, the adjusted EBITDA was 14.5%, broadly in line with last year. Sales growth and cost savings were offset by adverse currency impacts of 50 basis points due to the depreciation of growth geography currencies as well as the planned higher investments in advertising. We remain on track to deliver over 400,000,000 productivity savings this year and exceed the €1,800,000,000 productivity target set for the overall period of 2017 to 2020. In the Q3, our productivity program delivered €120,000,000 net savings. More specifically, procurement savings delivered €62,000,000 of bill of material savings. Net nonmanufacturing cost reduction amounted to €26,000,000 and the manufacturing productivity program contributed to €32,000,000 Restructuring, acquisition related and other charges were higher than the guided range mainly due to the provision of €38,000,000 related to a legal matter and an onerous contract provision of €57,000,000 in relation to changes in ventilator demand and certain aspects of the partial PA of the partial HHS contract termination. Net income amounted to €340,000,000 in the quarter. The adjusted diluted EPS from continuing operations grew 30% in Q3 to €0.60 Free cash flow was an inflow of €543,000,000 compared to €126,000,000 in Q3 2019. In the 1st 3 quarters of 2020, our free cash flow generation was around €800,000,000 €700,000,000 better than the same period of last year as a result of strong working capital performance. Our customers continue to face cash pressures due to the impact of COVID-nineteen, but we do not expect it to impact our total cash flow generation over a 12 to 18 month time horizon. Let me provide some guidance for certain areas of our business. Based on the announcement made so far, we continue to expect the full year gross impacts of tariff to be around €70,000,000 Including mitigating actions, we expect the net tariff impact to be around €40,000,000 in 2020. This is €30,000,000 lower than the net impact seen in 2019. In the segment Other, we expect an adjusted EBITDA loss of around €115,000,000 in 2020. This is €20,000,000 lower than our previous guidance due to cost savings delivered in the 3rd quarter. At EBITDA level, we now expect a net cost of around €240,000,000 for the full year 2020. This includes €50,000,000 to €60,000,000 of costs related to the separation of the domestic appliances business as explained before. Financial income and expenses are expected to be a net cost of around €100,000,000 in 2020, which is €50,000,000 than our lower than our prior guidance mainly due to lower interest expenses paid and positive value adjustments of financial assets. To summarize, we ended the quarter with 10% comparable sales growth and 15.4 percent adjusted EBITDA margin. For the Q4 of the year, we continue to expect to deliver growth and improved profitability for the group. Consequently, for the full year 2020, we expect to deliver modest comparable sales growth and an adjusted EBITDA margin of around the level of last year. We have seen increasing interest from investors seeking clarity on our post-twenty 20 performance road map. And as Frans mentioned, we decided to announce our targets for accelerated growth, higher profitability and improved cash flow today to give you sufficient time to prepare for an engaging dialogue during our Capital Markets Day on the 6th November. We request you to kindly reserve your questions on the performance road map for the Capital Markets Day so that we can focus today's Q and A on the Q3 performance and the outlook for the year. Due to the current restrictions around COVID-nineteen, we will have a virtual Capital Markets Day this year. Despite the change in format, we will have sufficient time for Q and A and interaction. Additionally, we will hold a series of fireside chats during the weeks following the CMD to be hosted by France and our segment leaders. More information on these events are published on our Investor Relations website. To conclude, I want again to thank our customers for their support as well as our employees for how they have stepped up to deliver against our triple duty of care during these difficult times. This has also been reflected in our high employee engagement scores. With that, we'll now open the line for your questions. Thank you. Thank you, sir. The first question comes from Veronika Dubajova from Goldman Sachs. Please state your question. Good morning and thank you for taking my question. Can we please start just I'd love to understand, Franz, what you're seeing a little bit from a hospital CapEx perspective, obviously, the D and T order momentum, big improvement versus Q2. But if you can give us a little bit of sense for how it progresses as you move through the months and your degree of confidence in order growth either turning neutral or positive in the Q4, which I think was your original expectation a quarter ago. That would be a great place to start. And then I have a follow-up after that, if that's all right. Okay. Hi. Good morning, Veronika. Well, the hospital CapEx has been directed to the acute care areas. So it's not that hospitals are not investing, but they have prioritized their emergency response. And that went to the expense of, let's say, the other modalities leading to some delays in installations. If we look at the plans that hospitals are making, then we see a great desire to invest in the more profitable elective procedure areas. So we actually do not expect a structural impact on hospital CapEx because this is the lifeline of the providers to generate the support to patients with chronic disease and generates their revenue streams. So while there is a delay, we don't think that, that is structural. And the improvement in D and T from Q2 to Q3 is a step in the right direction, is maybe a tad slower than what you all expected. But there's quite an old installed base in the world, especially in the United States and Europe, that is 10, 12 years old and that needs to be upgraded. And we if we look at our funnel, then we have every reason to believe that we can see the recovery of the D and T segment strongly. Now if you look, Ronica, at our guidance for next year, right, we are basically indicating that we expect 5% to 6% growth across D and T and Personal Health, while only Connected Care will be negative due to the very difficult compare. And that means that the totality of Philips will then be low single digit. And then from there on, we'll take the growth to the 5% to 6%. That indicates a strong confidence in our ability to get the order intake back up to a level to support that revenue growth. Let me pause there. That's very, very helpful. And can I just follow-up on that 2021 comment? I mean, obviously tough for us to see there's quite a lot of moving parts. But I'm just curious when it comes to profitability, your degree of confidence in that 60 to 80 basis points and potentially what might be some of the upside risk to that as you think about 2021 margins. Clearly, this year, you've demonstrated much better margin resilience than I think a lot of us would have expected at the outset. So just curious how you're thinking about that dynamic on the margin side for 2021? Yes. Well, I could, of course, say that this is not typically a question that belongs to Capital Markets Day, but let me at least say something about it, Veronika. It's a complex calculation, right, because the categories of patient monitoring and hospital respiratory care generated a lot of operational leverage in 2020. Some of that will fall away next year, although we do see resilience in the order funnel for patient monitoring, which because monitoring will get into our care settings. And I think the category will prove to be much more resilient than hospital ventilation. But then the other Connected Care modalities will come back up. We will provide at Capital Markets Day the typical bridge that you have gotten used to, and you will see there a balance coming from gross margin expansion, thanks to innovation, productivity gains because we see a lot of opportunity to continue to drive productivity programs over the next 5 years, in fact, and then other improvements. So I think yes, I'm being prompted here by Abhijit to also mention something about that while the, let's say, hospital ventilation goes down, actually sleep will come back up. And also, of course, the elective procedures recovering means that the high growth IGT devices will demonstrate strong growth and also cardiac ultrasound and MRI. So there's plenty of excitement brewing to underpin both growth and profit expansion. Again, let me pause there, Veronika. The next question comes from Michael Junglee from Morgan Stanley. Please state your question. Great. Good morning all. And I have 2 questions, both on Personal Health, please. The first one is, are the accounts receivables with your customers becoming an issue? Or have you taken already sufficient amount of provision against downfall debt charges going forward to avoid a negative surprise in the 4th quarter? And then question number 2 also in personal health is, how do your customers normally purchase for the Christmas period? Are most of, let's say, 90% of the orders sort of taken in Q3? And is this year different as customers wait to see how difficult COVID is and come in with some last minute orders for the Christmas period? Yes. Hi, Michael. Well, let me reassure you on the accounts receivable side because we have not seen difficulties on the Personal Health side. In April Q2, we were a bit worried about it, but we are in close contact with our customers, and we think this is entirely under control. On the Health Systems side, let me deviate slightly from your question and also cover the accounts receivable on the health systems side. There, we have seen some hospitals asking for help, but then we have been able to leverage our Phillips Capital Financial Services portfolio to help them out. And as a consequence, collections have been very strong. And you also see that our working capital has been very much under control. With regards to the PH ordering, of course, Q3 was very strong. There was an element of stocking up for this Q4 as is normal in a seasonal pattern as you get Prime Day and Black Friday and all these other things coming up. But I think what is very reassuring is that our sellout data is also strong, and that means that there is really underlying demand from consumers that want to buy into good personal care, put good personal hygiene and the products that we have on offer. Also, our domestic appliances business is very resilient, very strong recovery in Q3 across the entire portfolio. Yes, in passing, Michael, I mentioned that Prime Day is coming up, that as you know, Amazon has moved their Prime Day from Q2 to Q4. And so there's a lot of seasonal festivals coming up in the Q4. That's I think how I look at Personal Health. Okay. Franciscan, just because you guided for the Q4 to sort of a little bit of growth in Personal Health, are you taking a very conservative approach just in case things go the wrong way? Because the way it sounds right now that things could actually go a bit better than what you initially That guidance for Q4 is more because given the long shipping lines for Personal Health, the typical highest quarter in terms of selling in is the 3rd quarter, right? Therefore, we should not expect to repeat what we did in Q3 and Q4. So I would not label it as conservative on how we see consumer demand, but there is given the pipeline and the time lag, some of Q4 sales is already recorded in Q3 as a consequence. The next question comes from Patrick Wood from Bank of America. Please state your question. Perfect. Thank you for taking my questions. I'll just ask both upfront, if I can. First one, maybe China, a little bit of surprise there on at least on my end. What are you seeing there? I mean some of the data seems to suggest that the recovery is relatively strong, but I'm just kind of curious what you guys are seeing on the commercial side with consumers. And I was just a little surprised the weakness and how you feel about that going into next year? And then the second question is on Connected Care. Maybe just a little bit of help in terms of the phasing. Thank you for the commentary around Q4 still being strong growth. But should we expect generally over the next bunch of quarters, however you want to define it, growth to fairly meaningfully retreat down? I mean, I'm trying to get a sense of how sharp the drop off is. Yes. Hi, Patrick. Yes, China was a bit weak in the Q3, and we have some work to do on the Personal Health side in China, where we think we can step up the effectiveness of our marketing. We have several launches planned that will support the future. But and even though the gross numbers in China showed a good recovery, we feel that the market is not completely there yet. To a degree, that also applies to the health system side, where we saw growth a little bit softer than we had hoped for. So some work to be done in China. That is, of course, compensated by a very resilient Europe and United States market that we feel very good about. On Connected Care, I think it's a bit in line with the question from and the discussion we had on Veronika's question. So Abhijit already said that order book and orders and pipeline for Connected Care 4th quarter looks strong. I mentioned that I see monitoring also extend into other care areas and that, therefore, monitoring will be an area where we can see a longer demand cycle than hospital ventilation, which is a market that is going to be more saturated expectedly. However, the home ventilation and sleep categories, sleep apnea categories have suffered this year because of the COVID pandemic. Fewer sleep tests are being done. That means that there are quite a lot of patients that are under diagnosed and undertreated. We think that, that will get a big boost next year. Even so, the comparison from 2020 to 2021 will, of course, be very hard given the high revenue in CC this year. And therefore, we expect a negative growth in Connected Care in 2021 just because of the comparison. And therefore, Philips as a group comes into the low single digit growth rate for next year, while D and T and Personal Health are expected to grow in the 5% to 6% bracket. I hope that helps a bit. Thank you, Patrick. And then one more thing, Patrick. That is that we see strong demand for health informatics in Connected Care, telehealth related, and we certainly think that, that's on a winning streak with a lot of demand, and we think that's permanent. I mean that's the finally the acceleration that we have been hoping for and that we talked about many times in the past, when is it coming with all the investments done, and we think it's coming now. Yes. Maybe just to give a bit more color. So in patient monitoring, we are we have grown order intake, I think, 20% in the quarter, 50% the previous quarter. So we have good momentum there. So I think, Patrick, a good way to look at it is to compare the 2021 growth over 2019. And then you see if you take out the spike of 2020, you see really good steady growth. But yes, compared just mathematically to the spike of this year, there will be a decline. The next question comes from David Abington from JPMorgan. Please go ahead. Good morning, Jan. So thanks for taking the question. I just wanted to check if the consolidation in the imaging and radiotherapy space had changed your thoughts on the outlook for your D and T business and its competitiveness going forward. And associated with that, I just wondered if you recognized any one off costs in the quarter associated with aborted M and A attempts? That's an interesting question. Well, you're referring to the Siemens Varian deal, which is a big deal. But I bring to your recollection that we have a partnership in the radiotherapy area with Elekta. That partnership is going well. It serves us well. We do believe that the care pathways in oncology benefit from a good integration of technologies and software clinical decision support systems. We think that we can accomplish that through this partnership, and therefore nothing to report. And there are no charges for whatever in the in that space, so negative on your second question. And perhaps a wider perspective on the market of oncology. You know that we are already active in oncology in many years with the combination of our diagnostic informatics systems, therapy planning and more recently, oncology informatics, where we combine radiology, pathology and genomics and longitudinal data of patients. We combine it with the Dana Farber clinical decision support for decision making, and we are making a lot of headway in that segment. That's let me leave it at that. The next question comes from Hassan Alwakil from Barclays. Please state your question. Thank you for taking my questions. I have a couple, please. So firstly, where do you think ventilator capacity is now globally? And how much of the HHS contract cancellation do you think you can offset? And what about critical care capacity? And do you expect the strong growth in patient monitoring to persist? Secondly, on the medium term top line guidance, could you elaborate on the most significant drivers for your increased optimism and the narrowing of this range relative to your prior range? And also, what is the net margin benefit you have assumed from the disposal of domestic appliances at a group level, please? Thank you. All right. Awesome. Good morning. That's three questions, I think. First, the ventilator capacity. I don't 2019 and a kind of sevenfold increase this year, in which the cancellation of the 30,000 by the U. S. Is very sizable for 2019. The of the 2019 2021. Now that's a rough outline, and we are not the only one that is affected, by the way, by partial cancellation. Also 2 other vendors, it happened to them. And still, as Abhijit said, we still see orders coming in, in the Q4. There are still countries in the world that are under equipped when it comes to acute care. And depending on how COVID develops, it could well be that we will also see stockpile programs coming up from various governments. It's, for example, being debated in the European Commission. And if stockpile programs would emerge, then that could actually change the narrative I've just given for 2021. So it's a bit fluid situation. On monitoring, I think we can be much more optimistic longer term because historically monitoring was something for the intensive care department. In the meantime, we see more and more hospitals equipping patients also in the general ward, where the surveillance or the continuous surveillance of patients reduces the stress on hospital staff. It provides with the predictive analytics on how a patient is doing And the health economic benefits of monitoring in the general ward as well as the clinical benefits are well documented in the meantime. We also expect to see monitoring to take off in the out of hospital space with more and more chronic patients being monitored on a continuous basis or at least certainly after discharge for a while. These are new monitoring markets that will kick in also post COVID, And therefore, we are very we expect to be very positive about the monitoring and analytics marketplace for the years to come, certainly something where it will sustain that 5% to 6% growth. I mentioned hospital respiration to go down, but then the home ventilation and sleep apnea market will strongly recover, right? And therefore, we can be and then the health telehealth market will also get a boost. So we can expect Connected Care to be in that 5% to 6 percent bracket in 2022 after we have compensated for the spike. And you heard Abhijit say basically that if you think about Connected Care versus 2019, the next year should be in positive growth territory as well. I think first that we should be able to model that. The midterm optimism, well, over the last 5 years, we have been delivering consistently around 4.5% growth, and we have been stepping up investments, repositioned the portfolio towards higher growth categories. Let me just mention 1. IGT devices, double digit growth. This year, of course, a bit under pressure due to the postponement of elective procedures. But with all our exciting moves in Image Guided Therapy, we expect IGT overall to be high growth, but then IGT devices to be double digit. And it's we are now getting closer to the €1,000,000,000 in size for IGT devices. So it becomes a sizable business and really contributing to the overall growth of Philips. I mentioned health informatics as an area where we have invested quite a lot, and that is expectedly getting to much structurally a much higher growth ratio, right? And then there is all the other than Personal Health, structurally on a 5% to 6% growth. In fact, that should not be a surprise because also historically, we have been performing in that level. Then we see the strong performance with long term strategic partnerships. We recorded another 11 deals with customers across the world who believe in the fact that if you partner, you get better health productivity, better health outcomes. And the recurring revenue portfolio is increasing year on year, right? It makes us more resilient, but it also adds to the growth. So and we saw double digit growth in the solutions part of our portfolio. So plenty to think of when it comes to underpinning the midterm targets. And on the profitability side, of course, that goes back to the question on the bridge, partly driven by growth, partly by innovations and higher gross margins, partly by productivity programs that we will elucidate at the Capital Markets Day, but I can tell you that we see productivity programs to go through every year over the next 4 years. So also there, I think, are quite some. As it's called, as a Dutch expression, we have quite a few irons in the fire, as it is we have quite a few irons in the fire, as it is called. And then your third question on the DA impact. So the guidance is exclusive of DA. We expect to complete the deal by the Q3 of next year. DA is slightly below the average profitability of Phillips, therefore, maybe 10 basis points Yes, it's not material impact on the profitability. And it's a great asset, has nice growth. So also there, not a material impact in the portfolio mix. I hope, Hassan, that answers all your questions. The next question comes from Lisa Kley from Bernstein. Please state your question. Hi. Three questions, please. First of all, just a comment you made around the long term contract adding to growth. I guess this is more of an accounting question for Abhijit. So I assume you only book 1 year of revenues in the 1st year of, say, a 10 year contract. And versus selling that selling equipment outright to that customer, it actually would be a headwind to growth as you aren't accounting for the full value of all the unit placements in year 1. So actually, if we look at your long term your new mid term guidance and that includes an acceleration in these long term contracts, should we actually see that as a positive? Second question on Connected Care. Could you give us some guidance on the margins around Connected Care Informatics? I assume it hasn't been that profitable to date just because of investments required and being fairly small. But as we look out at that sort of 3, 4 years out, will that become a strong contributor to your EBITDA growth? And then lastly, you mentioned the old installed base of imaging equipment in the U. S. And Europe. What about patient monitors? I assume in order for hospitals to be able to take advantage of eICU and other platforms that they need to have newer monitors that are Wi Fi enabled, etcetera. So how should we think about the installed base that you have out there and how quickly that can turn over so that you can offer more of your sort of Software as a Service solutions? Okay, great. Lisa, let me start with questions 3 and then hand it over to Abhijit for 1 and 2. But the installed base in patient monitoring is not as old as, let's say, you see on the imaging side. And many of our patient monitoring systems are already connected to a central station, where on a departmental level, you can oversee the entire ICU ward. The interoperability with the electronic medical record is already arranged. Therefore, integration with hospital networks is completely there. That also given that we are so advanced, it actually helped us to be the market leader, right? So it's not correct to think of patient monitors as a old fashioned kind of a hardware device next to the bed. This is very advanced informatics applications. We do offer hospitals, of course, the newer systems, and we become more and more artificial intelligence enabled and predictive in their nature. So it is very exciting area. That's also why earlier in the questions, I said, I see sustained growth in Monitoring and Analytics. Abhijit? Yes. So Lisa, let me explain a bit about the long term strategic partnerships. It is not necessarily that they are as a service deal. And let me explain the difference. So some of them, we have a contract over 10 years to renew their equipment as and when necessary with newer technologies. So actually, it just locks us in with that hospital group over a period of 5 or 10 years where we just execute capital sales over that period, which is precommitted. So helps us to plan better, helps the hospital to plan better. Now in some cases, these hospitals also prefer over that period to have a fixed cash outlay through the period. And then we arrange it through Phillips Capital, so then it becomes a financing arrangement, which in most cases, we even offload to banks. So as far as our sales is concerned, it provides assurance of sales in the coming years but does not necessarily convert capital sales to, let's say, per use sales. There are a couple of sales that we do which is based on per use models. That has an impact, but it's in the larger and it will be bigger as we go forward. But in the larger scheme of things, not that big. And this can be also, let's say, collaborated with our overall solutions sales, which has grown significantly above our, let's say, equipment sales business. So if you look, I think few years ago, we had solution sales around the 28%. We are now north of 35%. Our target was to get to 35% this year. So actually, we grow our solutions business and recurring revenue business by more than double of what we are growing our equipment business. So that hopefully, that gives you a bit of more background as to why we have a higher level of confidence on the sales growth. We don't give specific guidance on Connected Care Informatics. But just to tell you, yes, it is a relatively small business. And with the expected growth coming forward, we expect it to get into margins in the range for a normal informatics business, which is in the teens. So there is a significant part of that improvement still to come. The next question comes from Ed Righley Day from Redburn. Please state your question. Good morning. Thank you. First of all, great to see explicit return on invested capital target as part of your midterm guidance. Frankly, far too rare to see that from companies we look at. Abhijit, can you just give us remind us of the base there from the 2019 in terms of your organic ROIC? And also in terms of organic ROIC, I presume that is including bolt ons, but nothing in terms of strategic acquisitions. Yes. Ed, maybe a couple of points. One, you said not many people have it, but we have actually always had a ROIC target. We ended 2019 with 14.8%. So in the mid teens, it will go slightly lower this year as we get the knock for Volcano into our net operating capital. But I think if what we do for our acquisitions, and we mentioned that very clearly because it's very difficult to give a prediction on how M and A will go, We have a 5 year period for which M and A is excluded. So from year 6 of an M and A, we put it into it as an organic target. So that's why you see this year, Volcano comes in. And then, let's say, over the course of the next 5 years, the other acquisitions that have happened subsequent to 2025 will keep coming into the numbers. So I think we would end this year if you around the mid teens, so maybe around the 13% if you especially if you exclude there was a big impact of a change in accounting. So when we had actually set out the targets, the IFRS guidance on capitalization of lease assets was not there. So if you keep it on that basis, we will end around the mid teens. That is what we had targeted. And then over the period, we expect it to go higher. The next question comes from Scott Bardo from Berenberg. Please state your question. Yes, thanks very much for taking the questions. So first question, please, just relates to the new midterm guidance you provided. And I appreciate you'll want to wait until the Capital Markets Day to outline your strategy and how you achieve that. But the question is, does the midterm targets imply a very heavy gearing to the Diagnostic and Treatment business to be achieved? If my calculations are correct, the Personal Health business already achieved a 19% margin last year when you exclude the Domestic Appliance business. And Connected Care, I think, is already for the 9 month at the upper end of the new margin range you set for 2025. So I just want to understand whether there is a very heavy weighting to DMT progression embedded within these targets, please. And the second question following on from that, I think that some of your competitors are launching new products in the diagnostic imaging space. And we've talked a little bit about broader consolidation in the channel. Can you give us an update please as to where Philips is within its innovation cycle here? Should we expect some new products to come at the RS and A and so forth? Thank you. Yes. Hi, Scott. Well, all three reporting segments will improve their profitability in the next period. And certainly, a big step up by D and T, as you imply, but also by Connected Care, right, which in fact we would all say has been underperforming up till 2019 and now has this nice boost from Acute Care, but still has to structurally further improve over the next years. So that underpins the group targets next to, of course, the operational productivity programs that we will elucidate at Capital Markets Day. The questions around launches and innovation, especially related to diagnostic imaging, We feel very confident about the product range. Launches of innovations are not necessarily restricted to RSNA. In fact, I think that's a little bit overrated as a launch platform. We have just launched the extension of the Azurion platform, which is several years ahead of the competition according to our customers and the feedback that we are getting. We have a very strong MRI portfolio. The demand, for example, the ambition, which is a helium free operations platform. And with the Compressed SENSE, the scan time is less, 50% less. So a very fast system. That demand is very strong. Now currently, of course, impacted by COVID. We have a renewal of our ultrasound portfolio. We have a strong slate of enterprise diagnostic informatics. The acquisition of Carestream has worked out very well. We get very good ratings on the ViewPax implementation. We see strong interest in the oncology and phonetics platform. So I can go on and on. The innovation portfolio is very strong, and it underpins basically the fact that we have been and are growing market share versus several, maybe not all, of our competitors. The next question comes from Max Yates from Credit Suisse. Please state your question. Thank you. Just my first question is on the D and T margins. And I just wondered if could you give a little bit more color about the headwinds that you faced in the quarter? Because I guess looking at it, Q2 had a greater sort of growth headwind, yet margins on a year on year basis were more resilient than what we saw in Q3. I imagine many of the same sort of trends of factory underutilization were there in Q2. So I'd just like to understand a little bit better what happened this quarter and what was perhaps a headwind that we had this quarter that we didn't last? That's my first question. Hi, Max. So I think as we have seen, let's say, slower installs on diagnosis and treatment, we have adapted our supply chain a bit stronger in the Q3. So that gives a slightly higher impact on factory leverage. But also, I think, important to understand 2 more things. 1 is the mix. So let's say the more profitable categories of cardiac ultrasound or IGT, right, which are big drivers, they have suffered from low growth, and that has impacted us to a certain extent. And I had one and we have mentioned right through the crisis that we are not scaling back on R and D, and that's linked to Frans's reply that he just gave on the innovation pipeline. We know that there is a couple of tough quarters with demand getting postponed, but we want to come out with all innovations at the right time. So we are not delaying or postponing any R and D related investments that we have, And that also weighs a bit heavily. And if we as soon as we start getting elective procedures back and then there is a bit of installations which start going quicker, you will find it coming back in subsequent quarters with a higher leverage. So I think there's not more to it than that. Okay. And just my follow-up question is on the ventilator business. I mean, I think in 2019, we have the figure of it was around €300,000,000 I think you talked about the capacity earlier in this call. But could you give us given you should have good visibility on Q4 deliveries, just in absolute revenue terms, how big you expect that business to be and also contribution to adjusted EBITA this year would also be helpful. Just to understand where we are with that business today versus 2019 levels given your assumption of going back to those 2019 levels is probably a reasonable outlook. Yes. Let us come back to you on that on the Capital Markets Day because otherwise, we could get too much into the details of what's happening next year. That's a couple of weeks off. We'll give you a bit more color. But we have seen quite some increase this year, which would not come next year, maybe close to 3x of what we had last year. So that should give you, let's say, a good idea of how much to factor in. The next question comes from Julien Dumas from Exane BNP Paribas. Please state your question. Hi, good morning, good and gentlemen. Thanks for taking my questions. I'm left with 2. 1 relates to the use of cash because you should get a pretty sizable amount of cash from the divestiture of domestic appliances early next year and that should probably take you to close to cash positive by the end of 2021. So how should we think about cash utilization in the near term? Is it more about shifting gears on M and A and possibly proceeding with a large M and A deal or more about cash flow distribution maybe? And the second question just relates to growth in PH in Q3. There was a slight discrepancy between Personal Care, Domestic Appliance and lower growth in our overall health care? Is that just a facing quarterly issue? Or is it the sign of a return of price pressure in that segment? Yes. Hi, Julien. Well, with regards to the use of cash, we will apply our capital allocation policy. So judging carefully what is driving the best return on investment. We have a balanced approach. We have been using all instruments in the past, ranging from returns to shareholders as well as organic and M and A. And it's very likely that we will continue to do that also in the future. And we are also quite comfortable with cash sitting on the balance sheet for a while, while we figure out what is the best way forward. Yes, the growth in Personal Health, very much driven by North America and Europe, strong across the range. And I referred that China was slow in Q3 and also their oral care, which is normally a very high growth category, was low. And that dented the global oral health care growth percentage. The next question comes from Falco Fred from Deutsche Bank. Please state your question. Thank you. Good morning. I would have one question left, please. It's very good to see you implementing new ESG targets. Could you share some more color on how you aim to measure those targets? And especially this target of improving the life of 2,000,000,000 people here by 2025, how do you measure this exactly? And what specific improvements in the life of these people are you looking for? Hi, Falko. Yes, we measure, of course, all our commitments. And at the Capital Markets Day, there will, in fact, be a presentation around ESG to bring it to the fore. The measurements are also elucidated on our website, among which the lives improved. And we track how many patients and consumers have benefit from our products, either directly because they own them or indirectly because they are either diagnosed or treated in a hospital. And then we take out double counts so that we cannot count the same person twice. Of course, that is a statistical method where we look at how often a consumer is touched by Philips Innovations. So I gladly refer you to the website for the exact calculation. It's, by the way, clear that to drastically increase the number of lives improved and given that you cannot double count people, that much of that growth also needs to come out of emerging markets in Asia as we are still, let's say, underpenetrated versus what the market share could become. So quite a lot of exciting growth opportunities there. And I was encouraged to see the wins now in Indonesia and in Vietnam. Indonesia, as you recall, where we sent Tim Preysman after his stint in Investor Relations. And already a few months later, he comes back with a big order. So that was very nice. The next question comes from Daniel Wendorff from Commerzbank. Please state your question. Yes, good morning and thanks for taking my questions. And 2, if I may. The first one on Diagnose and Treatment. How do you see your IGT portfolio develop in Q3 now? And is there a risk for that if hospitals get filled with COVID-nineteen patients again, as it looks like, at least in some European countries? My second question is on the patient monitoring business. How do you see the competitive market there develop with hospitals demanding apparently more holistic solutions and you're also moving monitoring solutions beyond ICUs. Is that having an impact there on the competitive environment? And maybe can you remind us again on the contribution of your Patient Monitoring business to your divisional sales and adjusted EBITA now going into 2021? Okay, Daniel. Yes, the IGT business, of course, is dependent on the return of elective procedures. About onethree of IGT is devices, and the devices are directly linked to the recovery of elective procedures. Our business is overweight in the United States, and there, the COVID improvements are still going in the right direction. And therefore, we also still expect a further recovery of elective procedures. On the whole, even when some countries in Europe are, let's say, scaling down, elective procedures may have some effect, but in the world, it may be limited. If the second wave accelerates, we could also see some risk to hospital installations, although at this moment, we have our revenue plan well backed up by the installation schemes agreed with customers, and we feel confident that we can deliver on the growth that we of course, the growth in Q4 will be lower than the growth in Q3, right, because we gave a full year guidance of low single digit growth for Philips. So you but we feel confident about our ability to deliver that. Then the question around monitoring. So I think we have been quite vocal that we see monitoring to become more and more an informatics application where we leverage big data to do predictive analysis on patients and how they are faring. And as that gets extended beyond the ICU, it becomes really an enterprise wide installation. And we have increasingly then to deal with the CIO of hospitals. And the architecture of patient monitoring is well catered for enterprise wide installations. And even we expect that as patients are monitored outside of the hospital that it will follow the architectural choices that hospitals have made for their hospital environment. Versus competition, Philips is ahead of the typical competitors who are still more in the stand alone monitors bedside and therefore more in the hardware age era than Philips, where we are much more in a client server model, if I use an informatics term, in how we measure and we put sensors on patients. That sensors give data that gets processed in our central systems. So we feel good about our competitive position. The contribution to margins, looking to have a G3? Yes. I think, let's say, Monitoring and Analytics contributes a little more than 40% to the Connected Care sales and a little bit more to the margin because, let's say, our informatics piece, as I mentioned earlier, is still low on profitability. So as that keeps increasing, let's say, over a period of time, you will find that the sales and profit contribution will equalize. But at this moment, it's a little bit above 40% of sales and slightly above that in terms of EBITDA. Due to time, we will take one last follow-up question from Veronica Jupajosa from Goldman Sachs. Please state your question. Great, guys. Thanks for squeezing me in at the end. If I can, just a follow-up on the midterm guidance. Just would be helpful to understand, Abhijit, I guess that 60 to 80 basis points margin improvement that you have, if that organic growth rate were to be more consistent with what you've 60 to 80 basis points look like? Would it be lower? And if so, how much? If you can help clarify that, that would be super helpful. And then just a quick follow-up on the Connected Care 4th quarter expectations. You said lower growth in Q3, but is it higher than Q2? Or is it lower than Q3 and Q2? Well, I have to check that. But regarding the midterm guidance, we give a range of 60 to 80 basis points. If it's a little bit low or a little bit higher, I think we will be in and around that range. So I don't want to get more specific around that at this time. I think And it is an all in number. Yes, yes. And I think Q4 will be similar to Q2 and not with the big bubble in Q3. So that's, I think, how you should look at Q4 for Connected Care. Thank you, Mr. Van Hatten and Mr. Bhattacharya. That was the last question. Please continue. Well, I'd like to thank everybody for tuning in this morning with us and to be part of the exciting Philips journey that with the new midterm targets will continue full force. And we look forward to engage with you at our Capital Markets Day, where we will be elucidating and underpinning providing underpinning on how we expect to achieve those targets. Thank you very much for today. This concludes the Royal Philips Third Quarter 2020 Results Conference